• Title/Summary/Keyword: immunology

Search Result 1,755, Processing Time 0.022 seconds

Involvement of Akt in mitochondria-dependent apoptosis induced by a naphthoquinone analog

  • Kang, Seung-Koo;Kim, Hae-Jong;Chun, Young-Jin;Kim, Mie-Young
    • Proceedings of the PSK Conference
    • /
    • 2003.10b
    • /
    • pp.158.2-158.2
    • /
    • 2003
  • Vitamin K-related analogs induce growth inhibition in various cancer cell lines. We report that 2,3-dichloro-5,8-dihydroxy-1, 4-naphthoquinone (DDN), a naphthoquinone analog, induces mitochondria-dependent apoptosis in human promyeloid leukemic HL-60 cells. DDN induced cytochrome c release, cleavage of Bid, and activation of caspases -8, -9 and -3. Cleavage of Bid, the caspase-8 substrate, was inhibited by the broad caspase inhibitor zVAD-fmk, whereas cytochrome c release was not affected by zVAD-fmk. (omitted)

  • PDF

Induction of cell death by 2,4,3',5'-tetramethoxystilbene in human acute promyelocytic leukemia (HL-60) cells and its mechanism.

  • Lee, Sang-Kwang;Kim, Mie-Young;Chun, Young-Jin
    • Proceedings of the PSK Conference
    • /
    • 2003.10b
    • /
    • pp.149.1-149.1
    • /
    • 2003
  • We have previously shown that 2,4,3',5'-tetramethoxystilbene (TMS), a synthetic trans-stilbene analogue, is one of the most potently selective inhibitor of human cytochrome P450 1B1 in vitro and in vivo. In the present studies, the apoptotic effects of TMS were investigated in HL-60 cells. The effects of TMS on the proliferation of HL-60 cells were determined with MTT assay. TMS exhibited cytotoxicity with an $IC_50$ value of 37 nM. Cotreatment with TMS and etoposide, a well-known anticancer drug significantly enhanced the cytotoxicity. (omitted)

  • PDF

Exploring Staphylococcus aureus Virulence Factors; Special Emphasis on Staphyloxanthin

  • Yehia, Fatma Al-zahraa A.;Yousef, Nehal;Askoura, Momen
    • Microbiology and Biotechnology Letters
    • /
    • v.49 no.4
    • /
    • pp.467-477
    • /
    • 2021
  • Staphylococcus aureus is a well-known pathogen that can cause diseases in humans. It can cause both mild superficial skin infections and serious deep tissue infections, including pneumonia, osteomyelitis, and infective endocarditis. To establish host infection, S. aureus manages a complex regulatory network to control virulence factor production in both temporal and host locations. Among these virulence factors, staphyloxanthin, a carotenoid pigment, has been shown to play a leading role in S. aureus pathogenesis. In addition, staphyloxanthin provides integrity to the bacterial cell membrane and limits host oxidative defense mechanisms. The overwhelming rise of Staphylococcus resistance to routinely used antibiotics has necessitated the development of novel anti-virulence agents to overcome this resistance. This review presents an overview of the chief virulence determinants in S. aureus. More attention will be paid to staphyloxanthin, which could be a possible target for anti-virulence agents.

Engineered adult stem cells: a promising tool for anti-cancer therapy

  • Youngdong Choi;Hong Kyu Lee;Kyung-Chul Choi
    • BMB Reports
    • /
    • v.56 no.2
    • /
    • pp.71-77
    • /
    • 2023
  • Cancers are one of the most dreaded diseases in human history and have been targeted by numerous trials including surgery, chemotherapy, radiation therapy, and anti-cancer drugs. Adult stem cells (ASCs), which can regenerate tissues and repair damage, have emerged as leading therapeutic candidates due to their homing ability toward tumor foci. Stem cells can precisely target malicious tumors, thereby minimizing the toxicity of normal cells and unfavorable side effects. ASCs, such as mesenchymal stem cells (MSCs), neural stem cells (NSCs), and hematopoietic stem cells (HSCs), are powerful tools for delivering therapeutic agents to various primary and metastatic cancers. Engineered ASCs act as a bridge between the tumor sites and tumoricidal reagents, producing therapeutic substances such as exosomes, viruses, and anti-cancer proteins encoded by several suicide genes. This review focuses on various anti-cancer therapies implemented via ASCs and summarizes the recent treatment progress and shortcomings.

Immunologic Basis of Type 2 Biologics for Severe Asthma

  • Soyoon Sim;Youngwoo Choi;Hae-Sim Park
    • IMMUNE NETWORK
    • /
    • v.22 no.6
    • /
    • pp.45.1-45.15
    • /
    • 2022
  • Asthma is a chronic airway inflammatory disease characterized by reversible airway obstruction and airway hyperreactivity to various environmental stimuli, leading to recurrent cough, dyspnea, and wheezing episodes. Regarding inflammatory mechanisms, type 2/eosinophilic inflammation along with activated mast cells is the major one; however, diverse mechanisms, including structural cells-derived and non-type 2/neutrophilic inflammations are involved, presenting heterogenous phenotypes. Although most asthmatic patients could be properly controlled by the guided treatment, patients with severe asthma (SA; classified as a treatment-refractory group) suffer from uncontrolled symptoms with frequent asthma exacerbations even on regular anti-inflammatory medications, raising needs for additional controllers, including biologics that target specific molecules found in asthmatic airway, and achieving the precision medicine for asthma. This review summarizes the immunologic basis of airway inflammatory mechanisms and current biologics for SA in order to address unmet needs for future targets.

Increased B Cell Understanding Puts Improved Vaccine Platforms Just Over the Horizon

  • Geneva Rose Notario;Kihyuck Kwak
    • IMMUNE NETWORK
    • /
    • v.22 no.6
    • /
    • pp.47.1-47.20
    • /
    • 2022
  • In the face of an endlessly expanding repertoire of Ags, vaccines are constantly being tested, each more effective than the last. As viruses and other pathogens evolve to become more infectious, the need for efficient and effective vaccines grows daily, which is especially obvious in an era that is still attempting to remove itself from the clutches of the severe acute respiratory syndrome coronavirus 2, the cause of coronavirus pandemic. To continue evolving alongside these pathogens, it is proving increasingly essential to consider one of the main effector cells of the immune system. As one of the chief orchestrators of the humoral immune response, the B cell and other lymphocytes are essential to not only achieving immunity, but also maintaining it, which is the vital objective of every vaccine.

The Immune Landscape in Nonalcoholic Steatohepatitis

  • Sowmya Narayanan;Fionna A. Surette;Young S. Hahn
    • IMMUNE NETWORK
    • /
    • v.16 no.3
    • /
    • pp.147-158
    • /
    • 2016
  • The liver lies at the intersection of multiple metabolic pathways and consequently plays a central role in lipid metabolism. Pathological disturbances in hepatic lipid metabolism are characteristic of chronic metabolic diseases, such as obesity-mediated insulin resistance, which can result in nonalcoholic fatty liver disease (NAFLD). Tissue damage induced in NAFLD activates and recruits liver-resident and non-resident immune cells, resulting in nonalcoholic steatohepatitis (NASH). Importantly, NASH is associated with an increased risk of significant clinical sequelae such as cirrhosis, cardiovascular diseases, and malignancies. In this review, we describe the immunopathogenesis of NASH by defining the known functions of immune cells in the progression and resolution of disease.

The Korean Academy of Asthma Allergy and Clinical Immunology guidelines for sublingual immunotherapy (대한천식알레르기학회 설하면역요법 진료지침)

  • Gwanghui Ryu;Hye Mi Jee;Hwa Young Lee;Sung-Yoon Kang;Kyunghoon Kim;Ju Hee Kim;Kyung Hee Park;So-Young Park;Myong Soon Sung;Youngsoo Lee;Eun-Ae Yang;Jin-Young Min;Eun Kyo Ha;Sang Min Lee;Yong Won Lee;Eun Hee Chung;Sun Hee Choi;Young-Il Koh;Seon Tae Kim;Dong-Ho Nahm;Jung Won Park;Jung Yeon Shim;Young Min An;Man Yong Han;Jeong-Hee Choi;Yoo Seob Shin;Doo Hee Han;Korean Academy of Asthma Allergy and Clinical Immunology (KAAACI) Allergen Immunotherapy and Allergen Working Group
    • Allergy, Asthma & Respiratory Disease
    • /
    • v.12 no.3
    • /
    • pp.125-133
    • /
    • 2024
  • Allergen immunotherapy (AIT) has been used for over a century and has been demonstrated to be effective in treating patients with various allergic diseases. AIT allergens can be administered through various routes, including subcutaneous, sublingual, intra-lymphatic, oral, or epicutaneous routes. Sublingual immunotherapy (SLIT) has recently gained clinical interest, and it is considered an alternative treatment for allergic rhinitis (AR) and asthma. This review provides an overview of the current evidence-based studies that address the use of SLIT for treating AR, including (1) mechanisms of action, (2) appropriate patient selection for SLIT, (3) the current available SLIT products in Korea, and (4) updated information on its efficacy and safety. Finally, this guideline aims to provide the clinician with practical considerations for SLIT.

The effect of Korean mistletoe extract M11C (non-lectin components) on IL-1β release and expression from macrophages (Macrophages로부터 IL-1β 분비 및 전사에 있어서 한국산 겨우살이 추출물 M11C (non-lectin components)의 효과)

  • Chang, Sung Ho;Jun, Myung Ha;Kang, Tae Bong;Mun, Se Hwan;Lee, Jun Ho;Seong, Nak Sul;Lee, Sung Tae;Kim, Jong Bae;Her, Erk
    • IMMUNE NETWORK
    • /
    • v.1 no.2
    • /
    • pp.170-178
    • /
    • 2001
  • Background: Korean mistletoe (Viscum album) extract has been found to posses immunostimulatory activity. In this study, Korean mistletoe extract, M11C (non-lectin components), was used to know whether this extract might activate mouse peritoneal macrophages to produce interleukin $1{\beta}$ (IL-$1{\beta}$). Methods: Hemagglutination assay was carried out to examine whether M11C contained a lectin or not. To know the effect of M11C on the production of IL-$1{\beta}$, the macrophages were treated by the M11C, and then collected the supernatant (M11C stimulated macrophages-conditioned media; MMCM). MMCM was analyzed for the IL-$1{\beta}$ quantification and mRNA expression by means of ELISA and RT-PCR, respectively. Results: Maximum effective dose and time of M11C on IL-$1{\beta}$ production from macrophages were $20{\mu}g/m{\ell}$ and 8 hours, respectively. This ELISA data was reconfirmed by immunoblotting assay. indicating that M11C is a good candidate for an immunomodulator. The dose and time dependent effects of M11C on the expression of IL-$1{\beta}$ mRNA from macrophages was also shown in expression of mRNA detected by RT-PCR. Treatment dose and time for the maximum expression of IL-$1{\beta}$ mRNA were $20{\mu}g/m{\ell}$ and 4 hours, respectively. Maximum gene expression of IL-$1{\beta}$ was much earlier than maximum production of it. Conclusion: As results, Korean mistletoe extract, M11C, may be used for an immunomodulator. This will be able to make up for and solve the problems caused by existent immunoagent with many adverse effects through many other studies in future including one molecule extraction.

  • PDF

Assessment of Relationship between Wilms' Tumor Gene (WT1) Expression in Peripheral Blood of Acute Leukemia Patients and Serum IL-12 and C3 Levels

  • Rezai, Omran;Khodadadi, Ali;Heike, Yuji;Mostafai, Ali;Gerdabi, Nader Dashti;Rashno, Mohammad;Abdoli, Zahra
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.16
    • /
    • pp.7303-7307
    • /
    • 2015
  • Background: Leukemia is a common cancer among children and adolescents. Wilms' tumor gene (WT1) is highly expressed in patients with acute leukemia. It is found as a tumor associated antigen (TAA) in various types of hematopoietic malignancies and can be employed as a useful marker for targeted immunotherapy and monitoring of minimal residual disease (MRD). In this regard, WT1 is a transcription factor that promotes gene activation or repression depending on cellular and promoter context. The purpose of this study was assessment of WT1 gene expression in patients with acute leukemia, measurement of IL-12 and C3 levels in serum and evaluation of the relationship between them. Materials and Methods: We evaluated the expression of WT1 mRNA using real-time quantitative RT-PCR and serum levels of IL-12 and C3 using ELISA and nephelometry in peripheral blood of 12 newly diagnosed patients with acute leukemia and 12 controls. Results: The results of our study showed that the average wT1 gene expression in patients was 7.7 times higher than in healthy controls (P <0.05). In addition, IL-12 (P = 0.003) and C3 (P <0.0001) were significantly decreased in the test group compared to controls. Conclusions: WT1 expression levels are significantly higher in patients compared with control subjects whereas serum levels of interleukin-12 and C3 are significantly lower in patients. Wt1 expression levels in patients are inversely related with serum levels of IL-12 and C3.